It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor and an oncogene product, which plays a pivotal role in tumor progression. Therefore, targeting persistent STAT3 signaling directly is an attractive anticancer strategy. The aim of this study is to test the efficacy of a novel STAT3 small molecule inhibitor, LLL12B, in suppressing medulloblastoma cells in vitro and tumor growth in vivo. LLL12B selectively inhibited the induction of STAT3 phosphorylation by interleukin-6 but not induction of STAT1 phosphorylation by INF-γ. LLL12B also induced apoptosis in human medulloblastoma cells. In addition, LLL12B exhibited good oral bioavailability in vivo and potent suppressive activity in tumor growth of medulloblastoma cells in vivo. Besides, combining LLL12B with cisplatin showed greater inhibition of cell viability and tumorsphere formation as well as induction of apoptosis comparing to single agent treatment in medulloblastoma cells. Furthermore, LLL12B and cisplatin combination exhibited greater suppression of medulloblastoma tumor growth than monotherapy in vivo. The present study supported that LLL12B is a novel therapeutic agent for medulloblastoma and the combination of LLL12B with a chemotherapeutic agent cisplatin may be an effective approach for medulloblastoma therapy.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Maryland School of Medicine, Department of Biochemistry and Molecular Biology, Baltimore, USA (GRID:grid.411024.2) (ISNI:0000 0001 2175 4264)
2 The University of Florida, Department of Medicinal Chemistry, College of Pharmacy, Gainesville, USA (GRID:grid.15276.37) (ISNI:0000 0004 1936 8091)
3 Johns Hopkins University School of Medicine, Department of Neurosurgery, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
4 The Ohio State University, Department of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, The Department of Pathology and Department of Biomedical Education and Anatomy, The College of Medicine, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
5 The Research Institute At Nationwide Children’s Hospital, The Ohio State University, Division of Hematology, Oncology and BMT, Department of Pediatrics, College of Medicine, Columbus, USA (GRID:grid.261331.4)